Showing results (1-10 of 12) with videos related to
Sort By:
Pageof 2
Clinical Pharmacology and Therapeutics|September 9, 2024
Partial Residual Plots as an Integrated Model Diagnostic Tool in Model-Based Meta-AnalysisJohn Maringwa, Paul Matthias Diderichsen, Chandni ValiathanClinical Pharmacology in Drug Development|February 21, 2022
Assessment of Effects of Investigational TAK-931, an Oral Cell Division Cycle 7 Kinase Inhibitor on the QTc Intervals in Patients With Advanced Solid TumorsXiaofei Zhou, Paul Matthias Diderichsen, Neeraj GuptaJournal of Clinical Pharmacology|September 26, 2021
Population Pharmacokinetics of TAK-931, a Cell Division Cycle 7 Kinase Inhibitor, in Patients With Advanced Solid TumorsXiaofei Zhou, Aziz Ouerdani, Paul Matthias Diderichsen, et al.Journal of Clinical Pharmacology|October 30, 2022
Population Pharmacokinetics of Mivavotinib (TAK-659), a Dual Spleen Tyrosine Kinase and FMS-Like Tyrosine Kinase 3 Inhibitor, in Patients With Advanced Solid Tumors or Hematologic MalignanciesCheryl Li, Kenny Watson, Shining Wang, et al.Clinical Pharmacokinetics|March 16, 2013
Characterizing systemic exposure of inhaled drugs: application to the long-acting β2-agonist PF-00610355Paul Matthias Diderichsen, Eugène Cox, Steven W Martin, et al.British Journal of Clinical Pharmacology|January 18, 2013
Predicted heart rate effect of inhaled PF-00610355, a long acting β-adrenoceptor agonist, in volunteers and patients with chronic obstructive pulmonary diseasePaul Matthias Diderichsen, Eugène Cox, Steven W Martin, et al.CPT: Pharmacometrics & Systems Pharmacology|October 24, 2025
Establishing Immune Correlates of Protection Against Respiratory Syncytial Virus Infection to Accelerate Vaccine Development: A Model-Based Meta-AnalysisYushi Kashihara, Li Qin, Shinji Shimizu, et al.Clinical Pharmacokinetics|February 15, 2015
Pharmacokinetics and Pharmacokinetic/Pharmacodynamic Modeling of Filgotinib (GLPG0634), a Selective JAK1 Inhibitor, in Support of Phase IIB Dose SelectionFlorence Namour, Paul Matthias Diderichsen, Eugène Cox, et al.Clinical Pharmacokinetics|April 7, 2019
Population Pharmacokinetic and Pharmacodynamic Analysis of GLPG1690, an Autotaxin Inhibitor, in Healthy Volunteers and Patients with Idiopathic Pulmonary FibrosisAmit Taneja, Julie Desrivot, Paul Matthias Diderichsen, et al.Clinical Pharmacology and Therapeutics|October 1, 2023
Model-Informed Selection of the Recommended Phase III Dose of the Inhibitor of Apoptosis Protein Inhibitor, Xevinapant, in Combination with Cisplatin and Concurrent Radiotherapy in Patients with Locally Advanced Squamous Cell Carcinoma of the Head and NeckYulia Vugmeyster, Abhigyan Ravula, Elisabeth Rouits, et al.Pageof 2